What Is Fayuvi and What Condition Does It Treat?

Fayuvi (generic name fostemsavir) is a prescription medication used in adults living with HIV-1 infection who have limited treatment options due to multidrug resistance or intolerance to other antiretroviral therapies. Approved by the U.S. Food and Drug Administration (FDA) in 2020, Fayuvi represents a new class of HIV medicines called gp120 attachment inhibitors. By blocking the virus’s ability to attach to immune cells, it helps reduce HIV levels in the blood and supports immune recovery.

How Fayuvi Works

• Mechanism of action: Fayuvi is converted in the body to temsavir, which binds to the gp120 protein on the HIV-1 virus surface.
• Prevents attachment: By occupying a key site on gp120, it stops HIV-1 from latching onto CD4 receptors on T-cells.
• Blocks entry: Without attachment, the virus cannot fuse with or enter the cell, halting its replication cycle.

This novel mechanism is especially valuable for people whose HIV has become resistant to other drug classes (e.g., reverse transcriptase inhibitors, protease inhibitors, integrase inhibitors).

Who Should Consider Fayuvi

Fayuvi is indicated for adults (18 years and older) with HIV-1 who:

• Are heavily treatment-experienced and have limited options due to multidrug-resistant virus
• Have documented failure of their current antiretroviral regimen
• Need a new agent to optimize viral suppression and immune recovery

Your healthcare provider will review your treatment history, resistance tests, and overall health before prescribing Fayuvi as part of a combination antiretroviral regimen.

Dosage and Administration

• Dose: 600 mg (two 300 mg extended-release tablets) taken twice daily
• With or without food: Can be swallowed whole; do not crush or chew
• Adherence: Consistent dosing at the same times each day is key to prevent resistance
• Missed dose: If within 8 hours of the scheduled time, take it right away. If more than 8 hours, skip and resume the next dose on schedule—do not double up.

Your provider may adjust your accompanying antiretrovirals but will keep the Fayuvi dose constant unless toxicity or interactions arise.

Efficacy and Clinical Evidence

The primary data on Fayuvi come from the BRIGHTE Phase III trial involving heavily treatment-experienced adults:

• Approximately 53% of participants achieved viral suppression (HIV-1 RNA < 40 copies/mL) at 24 weeks when Fayuvi was added to an optimized background regimen.
• CD4 counts increased, indicating immune recovery in many participants.
• Benefits continued through 48 and 96 weeks for those remaining on therapy.

While individual response varies, these results demonstrate Fayuvi’s ability to rescue viral control in people with few alternatives.

Potential Side Effects

As with any medication, Fayuvi can cause side effects. Most are mild to moderate and tend to appear early in treatment:

Common side effects (≥ 5% of people)

• Nausea
• Headache
• Diarrhea
• Dizziness

Serious but less common

• Immune reconstitution inflammatory syndrome (IRIS): An excessive immune response against infections as the immune system recovers
• QT interval prolongation: A heart rhythm change that may be significant when combined with other QT-prolonging drugs

If you experience severe symptoms—such as chest pain, fainting, or sudden mood changes—contact your doctor right away.

Precautions and Interactions

Before starting fayuvi, inform your provider about:

• Other medications: Strong CYP3A4 inducers (e.g., certain anticonvulsants, rifampin) can lower fostemsavir levels and reduce effectiveness.
• Cardiac history: Pre-existing QT prolongation or use of other QT-prolonging drugs may increase arrhythmia risk.
• Liver or kidney issues: While no dose adjustment is required for mild to moderate impairment, severe disease may warrant additional monitoring.
• Pregnancy and breastfeeding: Limited data exist; discuss potential benefits and risks with your doctor.

Always share a full medication list—including over-the-counter drugs and supplements—to avoid harmful interactions.

Monitoring While on Fayuvi

Regular check-ups help ensure Fayuvi is working safely and effectively:

• Viral load: Measured every 4–8 weeks until suppressed, then every 3–6 months
• CD4 count: Every 3–6 months to track immune recovery
• Liver and kidney tests: Baseline, then periodically or if clinically indicated
• Electrocardiogram (ECG): If you have risk factors for QT prolongation

Report new or worsening symptoms promptly, especially those involving heart rhythm, mental health, or signs of infection.

Special Populations

• Older adults: No specific dose changes, but monitor for increased sensitivity or drug interactions.
• Renal impairment: No adjustment for mild to moderate dysfunction; severe cases need careful evaluation.
• Hepatic impairment: Mild to moderate disease does not require a dose change; severe cases lack sufficient data—use caution.
• Pregnancy: Animal studies show no fetal harm, but human data are limited. Discuss family planning and breastfeeding considerations with your provider.

Getting Started and Next Steps

If you think fayuvi might be right for you:

1. Gather your treatment history and any recent resistance reports.
2. Schedule a consultation with an HIV specialist or your infectious disease doctor.
3. Consider doing a free, online symptom check, using the doctor approved Ubie Symptom Checker to review any current concerns before your visit.

Ultimately, managing HIV-1 is a team effort. Open communication with your healthcare provider ensures you receive the most appropriate medications and support.

Important: This information does not replace professional medical advice. Speak to a doctor about any life-threatening symptoms or serious health concerns. Your provider will help tailor treatment to your individual needs and monitor your progress on Fayuvi.